NCT03408899View on ClinicalTrials.gov

Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

April 19, 2019

Study Completion Date

April 19, 2019

Conditions
HIV Infections
Interventions
DRUG

PC-1005 gel

PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.

Trial Locations (2)

15213

University of Pittsburgh CRS, Pittsburgh

35294

Alabama CRS, Birmingham

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03408899 - Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults | Biotech Hunter | Biotech Hunter